Prevalence and associated factors of small intestinal bacterial overgrowth (SIBO) among systemic sclerosis (SSc) patients. The prevalence of SIBO, using the glucose H2 /CH4 breath test, is not common, however a positive result was associated with longer duration of disease. PubMed, Int J Rheum Dis, 02/06/2019. (Also see Bowel Dysfunction)
Peripheral blood eosinophilia is associated with the presence of skin ulcers in patients with systemic sclerosis (SSc). These results suggest that eosinophils are involved in the pathogenesis of vascular dysfunction of SSc. PubMed, J Dermatol, 02/04/2019. (Also see Digital Ulcers and Antibodies)
Reduced right ventricular output reserve in patients with systemic sclerosis (SSc) and mildly elevated pulmonary arterial pressures (mPAP). These findings give further evidence for the clinical relevance of mildly elevated mPAP in patients with SSc. PubMed, Arthritis Rheumatol, 01/07/2019. (Also see Secondary Pulmonary Hypertension)
sE-selectin, sIL-2R Levels Are Potential Markers of Localized Scleroderma Activity. Overall, the researchers suggested that both sE-selectin and sIL-2R are potential prognostic markers for localized scleroderma. Scleroderma News, 02/07/2019. (Also see Localized Scleroderma)
The impact of gastroesophageal reflux disease (GERD) symptoms in scleroderma (SSc): effects on sleep quality. Future studies should examine mechanisms underlying nocturnal GERD symptoms in SSc patients, and the impact of improved GERD symptom control on sleep quality. PubMed, Dis Esophagus, 01/31/2019. (Also see Reflux (Heartburn) and GERD and Sleep Disorders)
Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis (SSc) skin. These data provide a comprehensive portrait of the SSc skin microbiome and its association with local gene expression. PubMed, Arthritis Res Ther, 2019 Feb 6;21(1):49. (Also see Skin Fibrosis)
Type I interferon dysregulation in Systemic Sclerosis. Here we describe the evidence of Type I IFN dysregulation in SSc, revealed predominately by genetics and gene expression profiling. PubMed, Cytokine, 01/23/2019. (Also see Cytokines)
Incidental significant arrhythmia in scleroderma (SSc) associates with cardiac magnetic resonance measure of fibrosis and hs-TnI and NT-proBNP. This first implantable loop recorder study identified potentially life–threatening arrhythmias in asymptomatic SSc patients attributable to a primary SSc heart disease. PubMed, Rheumatology (Oxford), 01/28/2019. (Also see Complications with SSc Heart Involvement)
PU.1 controls fibroblast polarization and tissue fibrosis. Pharmacological and genetic inactivation of PU.1 disrupts the fibrotic network and enables reprogramming of fibrotic fibroblasts into resting fibroblasts, leading to regression of fibrosis in several organs. PubMed, Nature, 01/30/2019. (Also see Fibroblasts)
Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma (SSc). . Our results demonstrate that overexpression of EZH2 in SSc fibroblasts and endothelial cells is profibrotic and antiangiogenic. PubMed, Proc Natl Acad Sci U S A, 02/12/2019. (Also see Endothelin)
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: